Neovasc Inc. (NVCN)
(Delayed Data from NSDQ)
$0.50 USD
+0.01 (2.96%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.49 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.50 USD
+0.01 (2.96%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.49 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will Neovasc (NVCN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
by Zacks Equity Research
Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.
Company News For Jan 2, 2020
by Zacks Equity Research
Companies in the news are: NVCN, VIVE, SDRL, UROV
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of 23.77% and -41.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Neovasc (NVCN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Neovasc (NVCN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Nevro (NVRO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.
Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.
Integer (ITGR) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings Corporation (ITGR) reported adjusted earnings of 41 cents per share in the first quarter of 2017, a penny down on a year-over-year basis.
Abiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Abiomed posted a promising fourth quarter of fiscal 2017, with revenues beating the Zacks Consensus Estimate and earnings meeting the mark.
Allscripts (MDRX) Beats on Q1 Earnings, Revenues In Line
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX) reported first-quarter 2017 earnings of 10 cents per share, beating the Zacks Consensus Estimate by a penny.
Wright Medical (WMGI) Posts Wider-than-Expected Loss in Q1
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) reported adjusted loss of 9 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 8 cents.
PerkinElmer (PKI) Tops Q1 Earnings Estimates, FY17 View Up
by Zacks Equity Research
PerkinElmer Inc (PKI) reported first-quarter 2017 adjusted earnings of 55 cents per share, marginally beating the Zacks Consensus Estimate by a penny.
athenahealth (ATHN) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017.
AmerisourceBergen (ABC) Beats on Q2 Earnings, Lags Revenues
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) posted adjusted earnings of $1.77 per share in the second quarter of fiscal 2017, beating the Zacks Consensus Estimate of $1.71 and increasing 5.4% on a year-over-year basis.
DaVita (DVA) Earnings Miss Estimates, Revenues Beat in Q1
by Zacks Equity Research
DaVita Inc. (DVA) reported first-quarter 2017 adjusted operating earnings of 79 cents per share that missed the Zacks Consensus Estimate of 82 cents.
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.
Ecolab (ECL) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Ecolab Inc. (ECL) reported first-quarter 2017 adjusted earnings (excluding special gains, charges and tax items) of 80 cents per share, which missed the Zacks Consensus Estimate of 81 cents.